Pearls from the European Academy of Allergy and Clinical Immunology (EAACI) Congress, 2025

Authors

  • Manali Mukherjee, PhD Associate Professor, McMaster University

DOI:

https://doi.org/10.58931/cait.2025.5284

Abstract

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held in Glasgow, Scotland, United Kingdom from June 13 to 16, centred on the overarching theme of “Breaking boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future.” Indeed, this year’s theme emphasized the intersection of environmental health and allergic diseases. The vibrant congress featured several presentations on immunological diseases in both adult and pediatric populations, along with breakthroughs in clinical and translational domains. Key topics included asthma, allergy, chronic spontaneous urticaria, and current global challenges such as pollution and climate change. This report highlights several key studies, organized under three main themes: pediatric studies, biologics in combined airways disease, and biomarkers.

Author Biography

Manali Mukherjee, PhD, Associate Professor, McMaster University

Dr. Mukherjee is an Assistant Professor in the Division of Respirology, Department of Medicine, and a translational scientist affiliated with the Research Institute of St. Joe’s, Hamilton. She has demonstrated expertise in investigating inflammatory mechanisms of chronic respiratory diseases, in particular autoimmunity, response to treatment and development/validation of clinical biomarkers. Her research has identified the presence of localized autoimmune responses in the airways of patients with complex airways disease and determined their pathogenic role in driving disease severity. Of recent, she has identified autoimmune responses in acute-severe COVID and linked autoimmunity with post-acute COVID-19 sequelae (or Long COVID). In the field of respiratory medicine, she published ~65 manuscripts, and in the past 5 years these have accumulated >2500 citations (Google Scholar h-index 24, i10-index 40). Dr. Mukherjee’s research program focuses on “Lung autoimmunity and biomarkers”. She is a past recipient of the Emerging Researcher Award in Allergic Asthma awarded conjointly by the Canadian Institutes of Health Research (CIHR) and the Canadian Asthma, Allergy and Immunology Foundation (CAAIF). Her lab is funded by federal and non-federal sources including CIHR-ICRH and industry. Dr Mukherjee was recently named the AstraZeneca Chair in Respiratory Diseases (2023–2028).

References

Indolfi C, Klain A, Miraglia Del Giudice M, De Filippo M, Marseglia A, Marseglia GL, et al. The use of biologic therapies in pediatric severe asthma. Expert Rev Respir Med. 2025:1–11. doi:10.1080/17476348.2025.2535182

Schachner LA, Andriessen A, Benjamin L, Gonzalez ME, Kwong P, Lio P, et al. SAIGE II: the role of Staphylococcus aureus in skin barrier dysfunction and the development and severity of atopic dermatitis in young children. J Drugs Dermatol. 2025;24(8):810–816. doi:10.36849/jdd.8968

Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971–983. doi:10.1182/blood.2022018546

Dunican EM, Watchorn DC, Fahy JV. Autopsy and imaging studies of mucus in asthma. lessons learned about disease mechanisms and the role of mucus in airflow obstruction. Ann Am Thorac Soc. 2018;15(Suppl 3):S184–s191. doi:10.1513/AnnalsATS.201807-485AW

Venegas Garrido C, Mukherjee M, Svenningsen S, Nair P. Eosinophil-mucus interplay in severe asthma: implications for treatment with biologicals. Allergol Int. 2024;73(3):351–361. doi:10.1016/j.alit.2024.03.001

Lipworth BJ, Greig R, Chan R, Kuo CR, Jackson C. Head-to-head comparison of biologic efficacy in asthma: what have we learned? Allergy. 2025;80(5):1226–1241. doi:10.1111/all.16537

Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390(10):911–921. doi:10.1056/NEJMoa2311155

Merkel PA, Nair PK, Khalidi N, Terrier B, Hellmich B, Bourdin A, et al. Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025. doi:10.1016/j.ard.2025.06.2131

Downloads

Published

2025-11-04

How to Cite

1.
Mukherjee M. Pearls from the European Academy of Allergy and Clinical Immunology (EAACI) Congress, 2025. Can Allergy Immunol Today [Internet]. 2025 Nov. 4 [cited 2025 Nov. 7];5(2):23–29. Available from: https://canadianallergyandimmunologytoday.com/article/view/5-2-Mukherjee

Issue

Volume 5, Issue 2, Fall 2025

Section

Articles